JP2008530120A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530120A5
JP2008530120A5 JP2007555276A JP2007555276A JP2008530120A5 JP 2008530120 A5 JP2008530120 A5 JP 2008530120A5 JP 2007555276 A JP2007555276 A JP 2007555276A JP 2007555276 A JP2007555276 A JP 2007555276A JP 2008530120 A5 JP2008530120 A5 JP 2008530120A5
Authority
JP
Japan
Prior art keywords
fluoro
benzyl
methyl
ylmethyl
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007555276A
Other languages
English (en)
Japanese (ja)
Other versions
JP5419355B2 (ja
JP2008530120A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/004879 external-priority patent/WO2006086705A1/en
Publication of JP2008530120A publication Critical patent/JP2008530120A/ja
Publication of JP2008530120A5 publication Critical patent/JP2008530120A5/ja
Application granted granted Critical
Publication of JP5419355B2 publication Critical patent/JP5419355B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007555276A 2005-02-10 2006-02-10 選択的な5ht2aアンタゴニストとしての置換されたビスアリールおよびヘテロアリール化合物 Expired - Fee Related JP5419355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65191105P 2005-02-10 2005-02-10
US60/651,911 2005-02-10
PCT/US2006/004879 WO2006086705A1 (en) 2005-02-10 2006-02-10 Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists

Publications (3)

Publication Number Publication Date
JP2008530120A JP2008530120A (ja) 2008-08-07
JP2008530120A5 true JP2008530120A5 (enExample) 2009-03-05
JP5419355B2 JP5419355B2 (ja) 2014-02-19

Family

ID=36577530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555276A Expired - Fee Related JP5419355B2 (ja) 2005-02-10 2006-02-10 選択的な5ht2aアンタゴニストとしての置換されたビスアリールおよびヘテロアリール化合物

Country Status (23)

Country Link
US (1) US7625889B2 (enExample)
EP (1) EP1851199B1 (enExample)
JP (1) JP5419355B2 (enExample)
KR (1) KR20070107037A (enExample)
CN (1) CN101115717A (enExample)
AR (1) AR052903A1 (enExample)
AU (1) AU2006213634A1 (enExample)
BR (1) BRPI0606740A2 (enExample)
CA (1) CA2598429A1 (enExample)
CR (1) CR9260A (enExample)
DO (1) DOP2006000032A (enExample)
GT (1) GT200600042A (enExample)
IL (1) IL185173A0 (enExample)
MA (1) MA29289B1 (enExample)
MX (1) MX2007008606A (enExample)
NO (1) NO20074583L (enExample)
PA (1) PA8662501A1 (enExample)
PE (1) PE20061088A1 (enExample)
RU (1) RU2007133655A (enExample)
TN (1) TNSN07272A1 (enExample)
TW (1) TW200640859A (enExample)
UY (1) UY29372A1 (enExample)
WO (1) WO2006086705A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
MX2008001778A (es) 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
US7829713B2 (en) * 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2007126964A2 (en) 2006-03-31 2007-11-08 Schering Corporation Kinase inhibitors
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP2027119A2 (en) 2006-05-18 2009-02-25 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010045190A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
CN104797332B (zh) 2012-11-13 2018-05-29 通用电气医疗集团生物工艺研发股份公司 多元阴离子交换基质
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN107778257A (zh) * 2016-08-29 2018-03-09 湖南华腾制药有限公司 一种哌嗪衍生物的合成方法
CN106977463A (zh) * 2017-05-31 2017-07-25 湖南华腾制药有限公司 一种联苯取代哌嗪衍生物的合成方法
WO2019040107A1 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
US12293809B2 (en) 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
WO2021038419A1 (en) * 2019-08-23 2021-03-04 Insilico Medicine Ip Limited Kinase inhibitors and methods of synthesis and treatment
WO2022249113A1 (ko) * 2021-05-25 2022-12-01 주식회사 자이메디 Aimp2-dx2와 kras의 결합을 억제하는 신규 화합물 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US6348485B1 (en) * 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
MXPA02000537A (es) * 1999-07-16 2004-09-10 Bristol Myers Squibb Pharma Co Heterobiciclos que contienen nitrogeno como inhibidores del factor xa.
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US6573049B1 (en) * 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU2002223968A1 (en) * 2000-12-21 2002-07-01 Warner Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
DE10209520A1 (de) * 2002-03-04 2003-09-25 4Sc Ag Neue Modulatoren von Kaliumkanälen
AU2003291403A1 (en) * 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
EP1678144A1 (en) * 2003-10-23 2006-07-12 Akzo Nobel N.V. 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX
CA2561628C (en) * 2004-04-01 2012-05-08 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов

Similar Documents

Publication Publication Date Title
RU2007133655A (ru) Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а
JP6170121B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
JP5847087B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
ES2534605T3 (es) Agentes receptores de la histamina H3, preparación y usos terapéuticos
ES2548250T3 (es) Quinazolinonas como inhibidores de prolilhidroxilasa
ES2353247T3 (es) Derivados de (1h-indol-7-il)-pirimidin-2-il-amino)metadona y compuestos emparentados como inhibidores del igf-ri, para el tratamiento de cancer.
ES2401550T3 (es) Inhibidores de proteína cinasa y uso de los mismos
ES2629414T3 (es) Derivados de tiazol
ES2486674T3 (es) Piperazinilazetidinilamidas heteroaromáticas y aromáticas como inhibidores de la monoacilglicerol lipasa
US20130023532A1 (en) Indazolyl-pyrimidines as kinase inhibitors
RU2007121505A (ru) Соединения и композиции как ингибиторы протеинкиназы
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
JP2008513514A5 (enExample)
ES2324710T3 (es) Indolinonas sustituidas con heterociclos y su uso como inhibidores de receptores de tirosina quinasa.
US20230046077A1 (en) 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
RU2010118018A (ru) Хиральные цис-имидазолины
JP2009531276A5 (enExample)
PE20081263A1 (es) DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO
US9145411B2 (en) Substituted amino-pyrimidine derivatives
BR122017003188A2 (pt) composto 1-{2-[4-(2-amino-5-cloro-3-piridinil)fenóxi]-5-pirimidinil}-3-[2-(metilsulfonil)-5-(trifluorometil)fenil]ureia, sal deste, composição farmacêutica compreendendo-os e uso destes para o tratamento de câncer
JP2009538877A5 (enExample)
JP2007519694A5 (enExample)
ES2711453T3 (es) Un derivado de indolinona como inhibidor de tirosina quinasa
JP2020503268A (ja) 選択的hdac1、2阻害剤としてのピペラジン誘導体
JP2016537324A (ja) シクロペンチルベンズアミド誘導体及びそれらの精神障害及び認知障害の治療への使用